3 results
Approved WMOPending
To evaluate the safety and tolerability of crovalimab compared witheculizumab
Approved WMOWill not start
Primary: Dose escalation part: To determine the MTD and/or RP2D of PDR001 in combination with regorafenib in patients with metastatic MSS CRC. Expansion part: To evaluate the efficacy based on overall response rate (ORR) of PDR001 in combination…
Approved WMOPending
To evaluate the efficacy of crovalimab compared to eculizumab